A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

BACKGROUND: Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the outcomes of moderate-severe COVID-19 disease. In the same cohort, the ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannata-Andía, Jorge B., Díaz-Sottolano, Augusto, Fernández, Pehuén, Palomo-Antequera, Carmen, Herrero-Puente, Pablo, Mouzo, Ricardo, Carrillo-López, Natalia, Panizo, Sara, Ibañez, Guillermo H., Cusumano, Carlos A., Ballarino, Carolina, Sánchez-Polo, Vicente, Pefaur-Penna, Jacqueline, Maderuelo-Riesco, Irene, Calviño-Varela, Jesús, Gómez, Mónica D., Gómez-Alonso, Carlos, Cunningham, John, Naves-Díaz, Manuel, Douthat, Walter, Fernández-Martín, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853840/
https://www.ncbi.nlm.nih.gov/pubmed/35177066
http://dx.doi.org/10.1186/s12916-022-02290-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853840/
https://www.ncbi.nlm.nih.gov/pubmed/35177066
http://dx.doi.org/10.1186/s12916-022-02290-8

Ejemplares similares